Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: (L773:1352 4585 OR L773:1477 0970) srt2:(2020-2024) > Autologous haematop...

Details
MARC

Das, J.Royal Hallamshire Hosp, Sheffield Teaching Hosp NHS Fdn Trust, Acad Dept Neurol, Glossop Rd, Sheffield, S Yorkshire, England; Univ Sheffield, Sheffield Teaching Hosp NHS Fdn Trust, Sheffield Inst Translat Neurosci, UK Acad Dept Neurol, Sheffield, S Yorkshire, England (author)

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis

Article/chapterEnglish2021

Publisher, publication year, extent ...

2021-02-10
SAGE Publications,2021
electronicrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-454502
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-454502URI
https://doi.org/10.1177/1352458520985238DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Background:Autologous haematopoietic stem cell transplantation (AHSCT) is an effective treatment for patients with multiple sclerosis (MS) who have highly active disease, despite the use of standard disease-modifying therapies (DMTs). However, the optimal time for offering AHSCT to patients with ‘aggressive’ MS is yet to be established.Objectives:The objective was to explore the safety and efficacy of AHSCT as a first-line DMT in patients with ‘aggressive’ MS.Methods:All patients with ‘aggressive’ MS who received AHSCT as a first-line DMT in five European and North American centres were retrospectively evaluated.Results:Twenty patients were identified. The median interval between diagnosis and AHSCT was 5 (1–20) months. All had multiple poor prognostic markers with a median pre-transplant Expanded Disability Status Scale (EDSS) score of 5.0 (1.5–9.5). After a median follow-up of 30 (12–118) months, the median EDSS score improved to 2.0 (0–6.5, p < 0.0001). No patient had further relapses. Three had residual magnetic resonance imaging (MRI) disease activities in the first 6 months post-transplant, but no further new or enhancing lesions were observed in subsequent scans.Conclusion:AHSCT is safe and effective as a first-line DMT in inducing rapid and sustained remission in patients with ‘aggressive’ MS.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Neurologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Neurology hsv//eng
Autologous haematopoietic stem cell transplantation
multiple sclerosis
aggressive multiple sclerosis
disease-modifying therapy
no evidence of disease activity

Added entries (persons, corporate bodies, meetings, titles ...)

Snowden, J. A.Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England (author)
Burman, Joachim,1974-Uppsala universitet,Landtblom: Neurovetenskap(Swepub:uu)joabu293 (author)
Freedman, M. S.Univ Ottawa, Dept Med Neurol, Ottawa, ON, Canada; Ottawa Hosp Res Inst, Ottawa, ON, Canada (author)
Atkins, H.Univ Ottawa, Dept Med Neurol, Ottawa, ON, Canada; Ottawa Hosp Res Inst, Ottawa, ON, Canada (author)
Bowman, M.Univ Ottawa, Dept Med Neurol, Ottawa, ON, Canada; Ottawa Hosp Res Inst, Ottawa, ON, Canada (author)
Burt, R. K.Northwestern Univ, Feinberg Sch Med, Div Immunotherapy, Chicago, IL 60611 USA (author)
Saccardi, R.Careggi Univ Hosp, Dept Cellular Therapies & Transfus Med, Florence, Italy (author)
Innocenti, C.Careggi Univ Hosp, Dept Cellular Therapies & Transfus Med, Florence, Italy (author)
Mistry, S.Sheffield Teaching Hosp NHS Fdn Trust, Acad Dept Neurol, Sheffield, S Yorkshire, England (author)
Laud, P. J.Univ Sheffield, Stat Serv Unit, Sheffield, S Yorkshire, England (author)
Jessop, H.Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England (author)
Sharrack, B.Sheffield Teaching Hosp NHS Fdn Trust, Acad Dept Neurol, Sheffield, S Yorkshire, England; Univ Sheffield, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England (author)
Royal Hallamshire Hosp, Sheffield Teaching Hosp NHS Fdn Trust, Acad Dept Neurol, Glossop Rd, Sheffield, S Yorkshire, England; Univ Sheffield, Sheffield Teaching Hosp NHS Fdn Trust, Sheffield Inst Translat Neurosci, UK Acad Dept Neurol, Sheffield, S Yorkshire, EnglandSheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England (creator_code:org_t)

Related titles

In:Multiple Sclerosis Journal: SAGE Publications27:8, s. 1198-12041352-45851477-0970

Internet link

Find in a library

Multiple Sclerosis Journal (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Das, J.; Snowden, J. A.; Burman, Joachim, ...; Freedman, M. S.; Atkins, H.; Bowman, M.; show more...; Burt, R. K.; Saccardi, R.; Innocenti, C.; Mistry, S.; Laud, P. J.; Jessop, H.; Sharrack, B.; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Neurology

Articles in the publication: Multiple Scleros ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se